XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Net revenues $ 3,661 $ 3,982
Cost of sales 1,921 2,104
Gross profit 1,740 1,878
Research and development expenses 225 254
Selling and marketing expenses 584 585
General and administrative expenses 296 290
Intangible assets impairments 149 79
Other asset impairments, restructuring and other items 128 137
Legal settlements and loss contingencies 1,124 104
Other income (52) (5)
Operating income (loss) (713) 434
Financial expenses, net 258 290
Income (loss) before income taxes (971) 144
Income taxes (benefit) 2 62
Share in (profits) losses of associated companies, net (21) (3)
Net income (loss) (952) 84
Net income (loss) attributable to non-controlling interests 3 7
Net income (loss) attributable to Teva $ (955) $ 77
Earnings (loss) per share attributable to ordinary shareholders:    
Basic $ (0.86) $ 0.07
Diluted $ (0.86) $ 0.07
Weighted average number of shares (in millions):    
Basic 1,107 1,099
Diluted 1,107 1,107